NICE rebuffs Yervoy

The U.K.'s NICE issued a preliminary appraisal recommending against Yervoy ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat advanced malignant melanoma in adults who have received prior therapy. The committee said the data did not compare Yervoy with drugs used to treat patients with advanced or metastatic melanoma, but NICE did not say what comparator should be used. Patients in the indication are usually treated with carboplatin-based chemotherapy or dacarbazine, or given best supportive care. ...